Pharmamarketeer

Roche’s Gazyva to treat lupus nephritis receives US FDA breakthrough therapy designation

Roche, a global pioneer in pharmaceuticals and diagnostics company, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva (obinutuzumab) for

Medhc-fases-banner
Advertentie(s)